|Articles|February 15, 2022

Utilizing Cord Blood for Treatment, A Woman is Considered Cured of HIV

This patient is the first mixed race woman to experience HIV-1 remission, and potentially opens up the door to others being treated with a novel treatment.

At today’s 2022 Annual Conference on Retroviruses and Opportunistic Infection (CROI), it has been reported that a woman was cured of HIV with the treatment of a haplo-cord transplant.

According to a report in the NY Times, the person is being reported as a middle aged woman of mixed race. She had leukemia and received cord blood to treat it.

The woman underwent "reduced intensity CCR5∆32/∆32 haplo-cord [stem cell transplant] SCT and achieved AML remission with a 100% CCR5∆32/∆32 CB chimerism by day 100 post-transplant and thereafter," according to the investigators. "She had early hospital discharge, no acute or chronic GVHD, and asymptomatic CMV and EBV reactivation," the investigators wrote.

Specifically, she is “ART-free HIV-1 remission for 14 months following CCR5∆32 homozygous cord blood (CB) and CD34-selected haploidentical stem cell transplant (haplo-cord SCT) for acute myeloid leukemia (AML),” the investigators wrote.

The presentation given at CROI was titled, HIV-1 Remission With CCR5∆32∆32 Haplo-Cord Transplant In a US Woman: IMPAACT P1107.

The transplant came from a partially matched donor, and the patient received blood from a family relative to offer immunity in the early stages of her post-transplant.

“This is the third known case of HIV-1 remission, the first known case in a woman of mixed race, and the first known case with haplo-cord CCR5∆32/∆32 SCT,” the investigators wrote. “Broader use of CCR5∆32/∆32 haplo-cord transplantation should be considered to achieve HIV-1 remission and cure for persons living with HIV-1 requiring SCT for other diseases.”

Previously, two other patients known as the London and the Berlin patients who were in HIV-1 remission were men.

This opens the door to both woman and people with different races to seek a novel treatment for potential “cure” or long-term HIV-1 remission.


Related to this article

Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.